Journal Pre-proof



Quantifying association of early proteinuria and estimated glomerular filtration rate changes with long-term kidney failure in C3 glomerulopathy and immune-complex membranous proliferative glomerulonephritis using the United Kingdom RaDaR Registry

Sherry Masoud, Katie Wong, David Pitcher, Lewis Downward, Clare Proudfoot, Nicholas J.A. Webb, RaDaR Consortium, Edwin K.S. Wong, Daniel P. Gale

PII: S0085-2538(25)00491-0

DOI: https://doi.org/10.1016/j.kint.2025.06.003

Reference: KINT 4287

To appear in: *Kidney International*

Received Date: 2 October 2024

Revised Date: 28 April 2025

Accepted Date: 6 June 2025

Please cite this article as: Masoud S, Wong K, Pitcher D, Downward L, Proudfoot C, Webb NJA, RaDaR Consortium, Wong EKS, Gale DP, Quantifying association of early proteinuria and estimated glomerular filtration rate changes with long-term kidney failure in C3 glomerulopathy and immune-complex membranous proliferative glomerulonephritis using the United Kingdom RaDaR Registry, *Kidney International* (2025), doi: https://doi.org/10.1016/j.kint.2025.06.003.

Quantifying association of early proteinuria and estimated glomerular filtration rate changes with long-term kidney failure in C3 glomerulopathy and immune-complex membranous proliferative glomerulonephritis using the United Kingdom RaDaR Registry

kidney INTERNATIONAL

ISN INTERNATIONAL SOCIETY OF NEPHROLOGY

Cohort

Total cohort n=371
C3G n=203
IC-MPGN n=168

Proteinuria analysis cohort
n=91
C3G n=44
IC-MPGN n=47

Median follow up time 11.0 years (IQR 7.4-15.1)

148/371 (40%) reached kidney failure

Methods

RaDaR collects retrospective and prospective data for patients recruited from 108 UK hospitals

Associations between **eGFR slope** and **proteinuria at 0-24 months** and kidney failure were examined using Kaplan-Meier analysis and Cox Regression

Outcomes

- There was **no difference** in progression to kidney failure between C3G and IC-MPGN groups (p=0.2057)
- **2-year eGFR slope** had a modest association with kidney failure.
- **Baseline urine protein-creatinine ratio** (UPCR) was not associated with kidney failure in either group.
- **Decrease in UPCR between 0-12 months** was associated with lower kidney failure risk in both groups.
- Those with a **UPCR <100mg/mmol** at **12 months** had a substantially lower risk of kidney failure **(HR 0.10 (95%CI 0.03-0.30)).**

C3G



IC-MPGN



Masoud et al, 2025

CONCLUSION Proteinuria a short time after diagnosis is strongly associated with long-term outcomes in C3G and IC-MPGN. Reaching a UPCR <100mg/mmol at 1 year is associated with a substantially lower kidney failure risk.

[QUERY TO AUTHOR: title and abstract rewritten by Editorial Office – not subject to change]

Quantifying association of early proteinuria and estimated glomerular filtration rate changes with long-term kidney failure in C3 glomerulopathy and immune-complex membranous proliferative glomerulonephritis using the United Kingdom RaDaR Registry

Authors

Sherry Masoud[1], Katie Wong[2], David Pitcher[3], Lewis Downward[4], Clare Proudfoot[5], Nicholas J.A. Webb[5], RaDaR Consortium[6], Edwin K.S. Wong[7], Daniel P. Gale[8]

[1]Centre for Kidney and Bladder Health, University College London, UK and National Registry of Rare Kidney Diseases, Bristol, UK

[2]Centre for Kidney and Bladder Health, University College London, UK and National Registry of Rare Kidney Diseases, Bristol, UK

[3]Centre for Kidney and Bladder Health, University College London, UK and National Registry of Rare Kidney Diseases, Bristol, UK

[4]National Registry of Rare Kidney Diseases, Bristol, UK

[5]Novartis Pharma AG, Basel, Switzerland

[6]Multiple Affiliations

[7]National Renal Complement Therapeutics Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK

[8]Centre for Kidney and Bladder Health, University College London, UK and National Registry of Rare Kidney Diseases, Bristol, UK

Correspondence to: Professor Daniel P. Gale, UCL Department of Renal Medicine, Royal Free Hospital, Rowland Hill Street, London, NW3 2PF, d.gale@ucl.ac.uk.

Running head: Outcomes of C3G and IC-MPGN within RaDaR

Abstract word count: 270

Manuscript Word Count: 4213

Tables: 3

Figures: 4

Abstract

Introduction: C3 glomerulopathy (C3G) and immune-complex membranous proliferative glomerulonephritis (IC-MPGN) are rare disorders that frequently result in kidney failure over the long-term. Presently, there are no disease-specific treatments approved for these disorders, although there is much interest in the therapeutic potential of complement inhibition. However, the limited duration and necessarily small size of controlled trials means there is a need to quantify how well short-term changes in estimated glomerular filtration rate (eGFR) and proteinuria predict the clinically important outcome of kidney failure.

Methods: We address this using longitudinal data from the UK Registry of Rare Kidney Diseases (RaDaR) involving retrospective and prospective data collection with linkage to hospital laboratories via automated feeds of 371 patients. Analyses of kidney survival were conducted using Kaplan–Meier and Cox regression with eGFR slope estimated using linear mixed models.

Results: In a median of 11.0 (inter quartile range 7.4-15.1) years follow-up, 148 patients (40%) reached kidney failure. There was no significant difference in progression to kidney failure between C3G and IC-MPGN groups. Baseline urine protein-creatinine ratio (UPCR), although high, was not associated with kidney failure in either group. Two-year eGFR slope had a modest association with kidney failure. In contrast, both 20%–50% and 50 mg/mmol reductions in UPCR between 0-12 months were associated with lower kidney failure risk in both groups. Notably, those with a UPCR under 100 mg/mmol at 12 months had a substantially lower risk of kidney failure (hazard ratio 0.10 (95% confidence interval 0.03-0.30).

Conclusions: Overall, proteinuria a short time after diagnosis is strongly associated with long-term outcomes and a UPCR under 100 mg/mmol at one year is associated with a substantially lower kidney failure risk.

Keywords: Rare kidney disease registry, membranoproliferative glomerulonephritis, C3 glomerulopathy, complement, dense deposit disease, C3

Lay summary

C3 glomerulopathy (C3G) and Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) are rare kidney conditions which frequently lead to kidney failure (KF). Little is known about how changes in proteinuria and kidney function early in disease course are associated with long-term risk of KF. This is particularly important in understanding how short-term results from clinical trials might translate into longer-term outcomes. We used data from 371 UK patients with C3G and IC-MPGN recruited to the National Registry of Rare Kidney Diseases (RaDaR) to investigate associations between change in proteinuria and eGFR slope from diagnosis to 6, 12 and 24 months and KF. Median follow-up time was 11.0 years, during which 40% of patients reached KF. We found that whilst 2-year eGFR slope had a modest association with KF, decrease in urinary protein levels (UPCR) between diagnosis and 12 months was strongly associated with lower KF risk. Those with a UPCR <100 mg/mmol at 12 months had a 90% reduction in their risk of KF.

Introduction

C3 glomerulopathy (C3G) and immune-complex membranoproliferative glomerulonephritis (IC-MPGN) are rare kidney disorders in which there is glomerular inflammation, increased mesangial matrix and cellularity, capillary wall thickening with deposition of immunoglobulins (in IC-MPGN) and/or complement C3 (seen in both C3G and IC-MPGN). C3G is further subdivided into C3 glomerulonephritis and dense deposit disease (DDD) based on electron micrographic appearances. Presentation typically includes proteinuria and/or other features of kidney disease such as hematuria, hypertension, or renal impairment. These conditions have a combined incidence of 3-5 per million population.[1,2] Although the biopsy features of C3G and IC-MPGN can also be seen in disorders in which there is sustained activation of the immune system (such as persistent infection or autoimmune disease) the diagnosis of primary MPGN in the UK is reserved for those cases in which an underlying cause of immune activation is not identified. Although in most cases the cause of C3G and IC-MPGN is unknown, abnormal activation of the complement alternative pathway is frequently present in both disease categories. This can be attributed to the development of autoantibodies, most commonly C3 Nephritic Factor or, less often, can be associated with Mendelian[3–9] or non-Mendelian rare or common genetic variants[10–14] affecting innate or adaptive immunity; with comparable prevalence of variants and autoantibodies reported in both disorders.[11,15,16] Together with the presence of C3 deposited in the kidneys in almost all cases and the frequent serological evidence of C3 consumption,[10,11,15,17] these data have provided a compelling rationale for therapeutic targeting of the complement system in these disorders.

While the clinical presentation and diagnosis of these disorders are well-established, long-term outcomes and prognostic features are less well understood, with the literature dominated by single-center series, or studies with limited follow-up, focusing on baseline predictors of disease progression and prone to ascertainment bias. Nonetheless, prognostic markers such as eGFR, hypoalbuminaemia, and biopsy findings of interstitial fibrosis and tubular atrophy, crescents, and segmental sclerosis[11,18–24] have been consistently shown to be associated with kidney failure (KF) in both adult and pediatric IC-MPGN and/or C3G cohorts.[12,19–25] Literature regarding baseline proteinuria is more conflicting: in a study of 156 patients with C3G or IC-MPGN, baseline proteinuria >2 g per day was independently associated with the composite outcome of doubling of serum creatinine or KF.[20] However, in a cohort of 111 US C3G patients and 164 from France the association of baseline proteinuria with KF was non-significant in the multivariable model.[18,25] Finally, the GLOSEN investigators demonstrated a ≥50% decrease in proteinuria over follow-up or within 6-12 months to be associated with a slower eGFR decline and lower risk of KF.[26,27]

While case series and small observational studies have suggested a potential benefit of corticosteroids and mycophenolate, response to treatment varies, and long-term outcomes remain poor. The nephrology community therefore awaits the results of several complement inhibition randomized trials. However, interpreting the potential clinical impact of an intervention for rare kidney diseases based on evidence of efficacy in a short (i.e., 0.5-2 year) clinical trial is often hampered by lack of direct data demonstrating efficacy in reducing the key clinically relevant outcome of KF. Thus, data are needed inform appraisal of the likely clinical impact of early surrogate endpoints (such as proteinuria and short-term changes in eGFR), amenable to study in relatively short duration trials with limited numbers of participants, on long-term outcomes such as KF. There is growing interest in the extent to which these endpoints can serve as reliable surrogates for hard kidney outcomes and thus inform regulatory decisions and healthcare planning.[28–30]

Both observational data and meta-analyses of controlled trial treatment effects have supported the use of eGFR slope,[31–33] and proteinuria in the context of CKD,[34] and IgA nephropathy.[35,36] Subsequently, IgA nephropathy therapies that demonstrate a short-term reduction in proteinuria in clinical trials can now apply for accelerated approval by the US Federal Drug Administration with full approval granted following confirmation that the drug slows disease progression as measured by eGFR decline over 24 months.

To address this unmet need in C3G and IC-MPGN, we analyzed longitudinal data from 371 incident patients enrolled in the UK National Registry of Rare Kidney Diseases (RaDaR) to quantify the relationships between early changes in proteinuria and eGFR with the clinically important outcome of KF long-term. This study addresses and quantifies Prentice's first tenet for surrogate endpoints: that a surrogate endpoint should have a strong association with a true outcome.[37] The subsequent tenet- that treatment effect on the surrogate must capture the treatment effect on the clinical outcome-is best achieved through meta-analysis of controlled trials and is beyond the scope of this study.[33,38] Additionally, while medication data enrichment within RaDaR is ongoing, current data limitations preclude robust analyses of therapies patients have been exposed to historically.

Methods

Data source

RaDaR recruits patients from 108 National Health Service (NHS) sites with both retrospective and prospective data collection through linkage with hospital laboratories for routine blood and urine test results via the UK Renal Data Collaboration, and with the UK Renal Registry (UKRR) for validated data on initiation of kidney replacement therapy (KRT), including data provided by NHS Blood and Transplant (NHSBT). Patients provide

written informed consent at recruitment. Details of recruitment characteristics and potential biases have been reported previously.[39]

Inclusion and exclusion criteria for RaDaR are detailed in Supplementary materials.

Study population

Data from all prevalent patients recruited to RaDaR with one of the above conditions and diagnosed between January 2000 (when proteinuria reporting to RaDaR was established) and December 2022 were extracted on 13th February 2025. Participants with an eGFR <15 ml/min per 1.73m^2 or receiving KRT at diagnosis were excluded.

Patients who could be reliably classified as either C3G (n = 203) or IC-MPGN (n = 168) by updated (post-2012) criteria[40] were included. Any patients in whom classification by updated criteria was unclear were grouped as "primary MPGN-Not Otherwise Specified" (primary MPGN-NOS) and data presented in supplementary materials. Diagnoses were established by review of histopathological and clinical records (detailed in **Figure 1**,[19,41] Supplementary methods).

All patients classified as either C3G or IC-MPGN had data linkage with the UKRR for data on KRT initiation and death.

A subset of these patients also had eGFR and proteinuria measurements available at diagnosis and at 12 months post diagnosis, which enabled analyses investigating the association between proteinuria, eGFR changes and kidney failure (KF) in this group.

Variable and outcome definitions

Baseline or diagnosis date was defined by kidney biopsy date or in the absence of this, date of diagnosis recorded in RaDaR. Time of diagnosis window was defined as +/-3-months from diagnosis date. eGFR was calculated from plasma creatinine results using CKD-EPI (2009) without race adjustment, or Schwartz equation for those ≤16 years.[42,43] KF was defined as dependance on KRT or eGFR ≤15 ml/min per 1.73m^2 maintained for at least 4 weeks.[44] Follow-up time was defined as time between date of diagnosis and last available test result, or whichever occurred first, KF or death from any cause.

Statistical Analyses

Categorical data were reported as frequencies (%) and medians (interquartile range) for non-normally distributed continuous data. Kaplan-Meier analyses were used to compare time to KF for C3G and IC-MPGN.

Univariable Cox modelling was used to identify risk factors associated with KF for each disease group. Variables specified a priori included: age, sex, chronic kidney disease (CKD) stage, complement C3 and 4, random urine protein creatinine ratio (UPCR) at diagnosis and at 12 months, immunosuppression within 1st year of diagnosis. Variables achieving a significance threshold of $P < 0.05$ were included in the multivariable model. A two-sided *P*-value of 0.05 was considered significant. To examine the association between UPCR and time to KF, Cox regression was used to investigate UPCR values, percentage change, and absolute reduction at different timepoints (diagnosis, 6-months and 12-months), adjusted for sex, age, UPCR and eGFR at diagnosis. A reduction of 50 mg/mmol (0.44g/g) is presented to examine the lowest prognostically meaningful change in UPCR. UPCR values at 12 months were examined in two ways: a) comparing individuals achieving a UPCR <100 mg/mmol and 100-300 mg/mmol with a reference group of those >300 mg/mmol; b) Comparing patients with UPCR <100 mg/mmol with those >=100 mg/mmol, and then repeating, using thresholds of 200 and 300 mg/mmol to dichotomise the patients. Inception time for the Cox model was diagnosis date, and patients were censored at death.

Annualized rate of eGFR loss (eGFR slope) was calculated over full duration of follow-up, comparing C3G and IC-MPGN groups, and for the first two years following diagnosis. A linear mixed model with random intercept and random slope was used to estimate each patient's eGFR slope. Patients were required to have at least 4 eGFR measurements for inclusion. The association of KF with eGFR slope over 2 years and with percentage change in eGFR at 2 years (sustained over a minimum of 90 days) was also investigated, adjusting for age, sex, and eGFR at diagnosis. Finally, the impact of eGFR variability on KF, as measured using the coefficient of variation (CV) and average real variability (ARV), was evaluated using Cox regression, adjusted for the same covariates.

A joint model was used to investigate the association of longitudinal UPCR during follow-up and KF, stratified by diagnosis group (details included in the Supplementary Materials).

Data availability for each variable is shown in Supplementary Table S1. The analyses were restricted to patients with complete data required for each calculation; multiple imputation has not been performed. Percentages and proportions are of those with data available.

Analyses were performed using SAS v9.4, STATA v16.1 and R v4.3.3.

Ethics

This report adheres to the Strengthening the Reporting of Observation Studies in Epidemiology (STROBE) statement. RaDaR has ethical approval as a research registry provided by NHS South-West Central Bristol Research ethics committee (14/SW/1088) and by the RaDaR and UKRR operational committees.

Role of funders

CP & NW are/were employees and shareholders of Novartis at the time of manuscript submission. Novartis funded part of the research presented here through a research collaboration. The objectives and protocol were developed jointly. The RaDaR team conducted all the analyses and developed the manuscript draft, and all authors discussed the data and provided comments on the manuscript.

Results

Demographics and baseline characteristics

371 patients were included, 203 (55%) with C3G and 168 (45%) with IC-MPGN. Of the patients with C3G, n = 138 (68%) had a C3GN subtype, and n = 65 (32%) DDD (**Table 1**). For 352 patients it was not possible to confirm a diagnosis of C3G or IC-MPGN; results for these patients (Primary MPGN-NOS') are presented in Supplementary Table S2. The median age at diagnosis for patients with C3G was 20 years (IQR 11-40) and 25 years (IQR 10-54) for those with IC-MPGN. Patients with DDD subtype had a younger median age at diagnosis than those with C3GN (14 years (IQR 10-34) vs. 24 years (IQR 14-46), respectively), and a higher percentage of patients diagnosed at <18 years old compared to patients with C3GN or IC-MPGN.

Approximately half of all participants were female (166/371, 45%); this proportion was lower in the C3GN sub-group (54/138, 39%). Median C3 levels at diagnosis were lowest in the DDD subgroup (0.36 g/l (0.12-0.73)), and median C4 levels lowest in patients with IC-MPGN (0.14 g/l (0.09-0.25).

At least one medication entry was available for 292/371 participants within the 1st year of diagnosis (Supplementary Table S1). Of those with data 127/292 (43%) received at least one immunosuppressant and 119/292 (41%) received corticosteroids alone or as combination therapy. 121/292 (41%) were recorded as receiving a renal angiotensin system (RAS) inhibitor within 1 year of diagnosis, however this could reflect incomplete medication data collection.

Kidney Replacement Therapy

Over the course of follow-up, 86/203 (42%) of participants with C3G and 62/168 (37%) with IC-MPGN experienced a KF event. Most had started KRT at time of analyses: (83/86 (97%) of those with C3G and 59/62 (95%) of those with IC-MPGN), with 2 deaths prior to KRT initiation.

Of those reaching KF, 27/86 (31%) with C3G and 14/62 (23%) with IC-MPGN were diagnosed in childhood (<18 years). Most patients with C3G began KRT on maintenance haemodialysis (47/83 (57%)), followed by 21/86 (24%) on peritoneal dialysis, and 15/86 (17%) received a pre-emptive kidney transplant. Proportions of patients starting on each modality were similar for IC-MPGN (Haemodialysis 32/59 (54%), Peritoneal Dialysis 17/59 (29%), Pre-emptive transplantation 10/59 (17%)). For those diagnosed in childhood, rates of pre-emptive transplantation were slightly higher (5/27 (19%) for C3G and 4/14 (29%) for IC-MPGN.)

Over the follow-up period, 60/86 (70%) of patients with C3G and 40/62 (65%) with IC-MPGN who reached KF underwent at least one kidney transplant. 5-year graft survival was 73% (95% CI 57%-83%) for C3G, 71% for IC-MPGN and 75% (95% CI 67-82) for both groups combined (Supplementary Figure S1). 25th centile time to graft failure for all subsequent transplants for C3G and IC-MPGN combined was 3.3 years (95% CI 0.7 – 3.6).

Risk Factors for Progression to Kidney Failure

Linear mixed models of eGFR slope over full duration of follow-up and Kaplan-Meier analyses demonstrated no statistically significant difference in progression to KF between patients with C3G and IC-MPGN (**Figure 2**).

Risk factors associated with progression to KF were investigated using univariable and multivariable models (**Table 2**). In the univariable models, age, CKD stage at diagnosis and UPCR levels at 12 months were independently associated with KF for both C3G and IC-MPGN, whereas UPCR levels at diagnosis, albumin, immunosuppression use within 1 year and complement C3 and C4 at diagnosis were not. In the multivariable models, female sex and lower CKD stage at diagnosis were associated with a lower hazard of KF for both C3G and IC-MPGN groups. UPCR <100 mg/mmol at 12 months was associated with a decreased hazard of KF for C3G, and there were no KF events in the <100 mg/mmol group for IC-MPGN. Results were similar for patients with primary MPGN-NOS (Supplementary Table S3).

To address whether changes in eGFR and proteinuria early in disease course are associated with long term development of KF, we utilized a subset of 91 patients for whom data on UPCR and eGFR at diagnosis and 1-year post diagnosis were available (C3G n = 44, IC-MPGN n = 47, **Table 1 and Figure 1**). Baseline characteristics of this subset of patients and the overall cohort were generally comparable (Supplementary Table S4), although the restricted cohort were younger and had higher recorded immunosuppression and RAS inhibitor use at 1 year. All subsequent analyses were performed on this subset of patients.

We first demonstrated that annualized eGFR slope calculated over the first 2 years following diagnosis was strongly associated with KF (C3G *P* = 0.0033, IC-MPGN *P* = 0.0132) (**Figure 3a**). However, an annual decline of 10 ml/min per 1.73m^2 over the first 2 years was associated with only a modest increase in KF hazard for both C3G (HR 1.68 95% CI 1.13-2.49) and IC-MPGN (HR 1.99 95% CI 1.28-3.10). As a sensitivity analysis, those with an eGFR >60 ml/min per 1.73m^2 at diagnosis were excluded, and subsequent point estimates were only marginally higher (Supplementary Figure S2). Replicating this in a prevalent cohort (diagnosed >1 year prior to inclusion) resulted in higher point estimates (Supplementary Figure S3). Results for sustained percentage change in eGFR at 2 years were more conflicting; percentage change in eGFR was associated with KF for C3G (*P* = 0.0022), but not IC-MPGN (*P* = 0.7342) (**Figure 3b**) or for both groups combined (*P* = 0.1210, Supplementary Figure S4). The distribution of participants' eGFR changes are available in Supplementary Figure S5. eGFR variability as measured by both CV and ARV was not associated with KF (Supplementary Figures S6 and S7).

Next, we examined changes in UPCR across diagnosis, 6-month, 12-month timepoints as may be presented in a clinical trial, excluding those with a UPCR <50 mg/mmol at diagnosis. As outlined, the objective was to quantify the KF hazard associated with increases and decreases in UPCR, regardless of why these may have occurred. The distribution of UPCR measurements in both the C3G and IC-MPGN cohorts across different timepoints can be found in Supplementary Figure S8, with a median UPCR of 532 mg/mmol (IQR 301-915) at diagnosis and 117 mg/mmol (IQR 55-321) at 12months for C3G, and median UPCR of 581 mg/mmol (IQR 310-847) at diagnosis and 102 mg/mmol (IQR 25-360) at 12 months for IC-MPGN. Absolute reduction of UPCR between 0-12months was significantly associated with lower risk of KF for both C3G and IC-MPGN patients (**Table 3**); a 50 mg/mmol decline was estimated to have an adjusted HR (95% CI) of 0.63 (0.50, 0.78) for the combined cohort. Additionally, whilst a 50% reduction in UPCR at 6 months did not reach statistical significance for either group, a halving of UPCR from diagnosis to 12 months and 6 to 12months was strongly associated with a lower rate of KF for both C3G (0-12 months: HR 0.40 (95% CI 0.23, 0.69) *P* = 0.001. 6-12 months: HR 0.33 (0.14, 0.76) *P* = 0.0097) and IC-MPGN patients (0-12 months: HR 0.22 (95% CI 0.1, 0.49) *P* = 0.0002. 6-12 months: HR 0.12 (0.03, 0.58) *P* = 0.0079). Forest plots demonstrating how this risk varies for a range of UPCR changes from diagnosis to 12 months are presented in Figure 3C with the distribution of UPCR changes in our cohort presented in Supplementary Figure S9.

From both a clinical practice and trial perspective, understanding the extent to which reaching certain thresholds diminishes KF risk can often be useful. **Figure 4** shows time to KF according to UPCR category for C3G and IC-MPGN. **Table 3** shows the KF hazard for those who reach a specific threshold of UPCR at 12 months, compared to those who do not reach that threshold, for the combined cohort and each group separately. For example, reaching a UPCR of <100 mg/mmol at 12 months was associated with a 90% lower rate of KF compared to patients achieving a UPCR >100 mg/mmol, for C3G and IC-MPGN combined (**Table**

3). Whilst reaching a UPCR of <200 mg/mmol and <300 mg/mmol at 12-months also showed similarly large reductions in the hazard of KF, this is likely due to inclusion of patients achieving a UPCR <100 mg/mmol in those groups; when comparing patients reaching a UPCR of 100-300 mg/mmol to a reference group of >300 mg/mmol, we found no statistically significant reduction in KF risk at these thresholds (**Table 2**).

To verify this finding was not driven by inclusion of low-risk participants whose UPCR started and remained low, we performed a sensitivity analysis excluding those with a UPCR <100 mg/mmol at diagnosis (Supplementary Table S5), which showed similar results. Results were comparable in the MPGN-NOS cohort (Supplementary Table S6).

Joint models showed a significant association of UPCR during total follow up with KF, adjusting for age, sex and eGFR at diagnosis (Supplementary Table S7). Adjusted HRs (95% CI) for a halving of UPCR were 0.24 (0.10, 0.56) for C3G and 0.54 (0.36, 0.80) for IC-MPGN.

Discussion

We present long-term longitudinal data from 371 C3G or IC-MPGN patients within the UK National Registry of Rare Kidney Diseases (RaDaR). Using an incident cohort, we provide valuable insights into the natural history of these ultra-rare disorders, expanding on small-scale observational studies[9,18,20,26] and providing quantitative estimates for the relationship of early surrogate endpoints on KF hazard. We present analyses of C3G and IC-MPGN combined and separately for reference, given evidence of overlapping pathogenesis, specifically complement pathway dysregulation and thus suitability for inclusion in targeted therapy trials.[10,11] A particular strength of this study is the median follow-up 11.0 years (7.4-15.1), during which 40% of participants reached KF, illustrating the significant unmet need for effective treatments in these disorders.[45] Recent results from the GLOSEN registry showed similarly high rates of KF (70% kidney survival over a median follow-up of 5.4 years, compared to 73% 5-year kidney survival (95% CI 68%–78%) in this cohort), despite significantly higher rates of corticosteroid use (84%–90% compared to 38%–49% in this cohort), perhaps suggesting limited effectiveness of current treatments. This is notably compounded by a reduced five-year first allograft survival of 75% compared with 84%–87% five-year graft survival for all (adult or pediatric) deceased donor recipients in the UK,[46,47] and evidence that fewer paediatric patients achieve the optimal treatment of pre-emptive transplantation (22%) compared to >30% of the overall incident UK paediatric KRT population,[48] although this proportion can be as low as 3% for some glomerular diseases.

In a multivariable cox regression model, Female sex was associated with lower risk of KF for both disease groups. These differences are not explained by earlier ascertainment: whilst Females had a younger median age at diagnosis (Females 18 years (IQR 10-49) Males 24 (12-46), $P = 0.27$), and better baseline kidney function (median eGFR at diagnosis: Females 66 (IQR 39-99), Male 64 (40-104), $P = 0.80$), these differences did not reach statistical significance. To our knowledge, this is the first study to describe sex differences in kidney outcomes in C3G and IC-MPGN, and verification in other cohorts would be beneficial.

Consistent with previous studies,[11,49] we show no significant difference in time to KF between C3G and IC-MPGN patients nor in mean eGFR slope over the first 5 years of follow-up and that eGFR and proteinuria are strongly associated with long-term outcomes in both groups.[19,22] However, our analysis showed stronger relationships of these parameters at 6-24 months with long-term risk of KF, with the association of proteinuria (and changes in proteinuria) particularly significant. Addressing the utility of these endpoints in a disease specific context, we show that while eGFR slope early in disease course is strongly associated with KF, the magnitude of the effect is relatively modest, even over two years, compared to change in proteinuria over 1 year. This remains the case irrespective of whether baseline eGFR is above or below 60 ml/min per 1.73m^2 as has also been shown using CKD data,[31] although the effect of eGFR slope on KF was more marked in a prevalent cohort (Supplementary Figure S3). This suggests that eGFR slope has more limited predictive power forC3G and IC-MPGN compared to other kidney disorders, particularly early in the disease.

As previously reported,[19,26] proteinuria at baseline was not associated with KF, whereas proteinuria reduction at 12 months was. This complements previous reports from the GLOSEN registry, which showed a ≥50% reduction in proteinuria at 12 months was associated with a lower risk of KF (HR 0.83 95%CI (0.69–0.95)).[26] We further demonstrate the novel finding that smaller reductions in proteinuria as little as 50 mg/mmol at 12 months were statistically significantly associated with lower risk of KF, as was a percentage decrease in UPCR as little as 20%, although most patients in the cohort had larger changes in proteinuria (Supplementary Figure S9).[27] By determining how KF risk changes across a range of absolute and percentage decreases in proteinuria, even for reductions smaller than the ≥50% decrease shown in previous studies,[27] our results help enable more accurate prognostication clinically and more comprehensive appraisal of clinical trial results.

Achieving a threshold UPCR of <100 mg/mmol by 12 months was particularly strongly associated with lower rate of KF events (HR 0.10 (95%CI 0.03-0.30), $P < 0.0001$. Therefore, if proteinuria is shown in clinical trials to be reduced to similarly low levels by therapies that act by reducing disease activity as compared to standard of care, it is logical to infer that long-term KF hazard will be similarly reduced, potentially supporting the use of this accessible endpoint in future trials as a surrogate for KF. However, the thresholds used in our study are currently demonstrative, and validation in other cohorts are needed before use as clinical trial endpoints or treatment targets.

Our findings must be considered in the context of the limitations inherent in registry studies including incomplete data. The latter is mitigated through data linkages with UKRR and NHSBT which provide validated long-term KF endpoints for all UK patients as well as increasing prospective data collection via automated laboratory feeds from NHS hospitals. However, this remains a real-world dataset in which standard of care may impact the availability of eGFR and UPCR data at timepoints, as may patient or disease characteristics. It is most representative of the population and clinical practice patterns in the UK, which may be different in other settings. We have presented analyses examining the association between eGFR and UPCR changes early in disease and KF using a restricted cohort with data available at all requisite

timepoints. This cohort was younger at diagnosis and more likely to be recorded as receiving medications in their first-year post-diagnosis than those without available data, and may therefore represent a population with earlier disease onset and a more intensive standard of care. Whilst our analyses are particularly pertinent to this population, these characteristics should be taken into consideration when interpreting our results.

Additionally, RaDaR does not yet collect data on frailty which may account for some heterogeneity in data collected across sites, and medication data was limited. The additive prognostic value of autoantibody or genetic variant status could not be assessed with this dataset. Finally, whilst beyond scope this study, further work to assess whether treatment effects on intermediate endpoints predict treatment effects on KF may enable upgrade of proteinuria from a "reasonably likely" to a "validated" endpoint as indicated in the Biomarkers, Endpoints, and other Tools Resource.[47]

In conclusion, using real-world data from RaDaR, we provide quantitative descriptions of the relationships between early changes in both eGFR and proteinuria, and long-term renal outcomes in incident patients with C3G and IC-MPGN. Across a range of measures, we demonstrate that proteinuria a short time after diagnosis is strongly associated with long-term outcomes and notably that UPCR <100 mg/mmol at 1 year is associated with substantially lower risk of KF progression, and that even small reductions in proteinuria could significantly reduce long-term KF risk.

Disclosure Statement

CP and NW are/were employees and shareholders of Novartis AG who part funded the analysis and who have applied for marketing authorization for a therapy for C3 glomerulopathy. EKSW declares receiving fees for consulting and presenting from Novartis, Apellis, Alexion, SOBI, Arrowhead and Biocryst. DPG declares support from St Peter's Trust for Kidney Bladder and Prostate Research, Novartis AG, Medical Research Council, Kidney Research UK, Kidney Care UK, and Polycystic Kidney Disease Charity (payments to institution), chairs the Rare Diseases Committee of the UKKA and has received fees for consulting and presenting from Novartis, Alexion, Calliditas, Sanofi, Britannia, SOBI and Travere. All other authors declare no competing interests as they relate to the current manuscript.

Data sharing statement

The RaDaR database is hosted by the UK Renal Registry and its metadata are available via https://rarerenal.org. Individual-level data are not available for export. Proposals to perform analyses

using the data for academic, audit or commercial purposes can be made to the RaDaR Operations Group via https://rarerenal.org

Acknowledgements

The authors thank all RaDaR participants, their family members, and the UK Renal Registry staff. RaDaR is funded by the UK Kidney Association, UK Medical Research Council, Kidney Research UK, Kidney Care UK, and the Polycystic Kidney Disease Charity.

Funding

RaDaR was originally funded by the Medical Research Council, Kidney Research UK, Kidney Care UK and the Polycystic Kidney Disease Charity and is now managed and funded by the UK Kidney Association. RaDaR has received ad hoc funding for individual project work and annual funding from various charities to maintain the registry on the National Institute for Health Research portfolio. The analysis for this manuscript was part funded by Novartis AG.

Authors Contributions

DPG conceived the study and acquired funding. SM, KW, LD, and DP curated data, performed formal analyses, accessed, and verified the data. DPG and SM wrote the initial draft. EW, CP, and NW assisted with analysis and reviewed and edited the manuscript. DPG and SM had final responsibility to submit for publication.

Supplementary Material

Supplementary material is available online at www.kidney-international.org.

References

1. Briganti EM, Dowling J, Finlay M, et al. The incidence of biopsy-proven glomerulonephritis in Australia. *Nephrol Dial Transplant*. 2001;16(7):1364-1367. doi:10.1093/NDT/16.7.1364
2. Sethi S, Zand L, Leung N, et al. Membranoproliferative glomerulonephritis secondary to monoclonal gammopathy. *Clin J Am Soc Nephrol*. 2010;5(5):770-782. doi:10.2215/CJN.06760909
3. Gale DP, De Jorge EG, Cook HT, et al. Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. *Lancet*. 2010;376(9743):794-801. doi:10.1016/S0140-6736(10)60670-8

4. Malik TH, Lavin PJ, De Jorge EG, et al. A hybrid CFHR3-1 gene causes familial C3 glomerulopathy. *J Am Soc Nephrol*. 2012;23(7):1155-1160. doi:10.1681/ASN.2012020166

5. Chen Q, Wiesener M, Eberhardt HU, et al. Complement factor H-related hybrid protein deregulates complement in dense deposit disease. *J Clin Invest*. 2014;124(1):145-155. doi:10.1172/JCI71866

6. Ault BH, Schmidt BZ, Fowler NL, et al. Human factor H deficiency. Mutations in framework cysteine residues and block in H protein secretion and intracellular catabolism. *J Biol Chem*. 1997;272(40):25168-25175. doi:10.1074/JBC.272.40.25168

7. Tortajada A, Yébenes H, Abarrategui-Garrido C, et al. C3 glomerulopathy-associated CFHR1 mutation alters FHR oligomerization and complement regulation. *J Clin Invest*. 2013;123(6):2434-2446. doi:10.1172/JCI68280

8. Martínez-Barricarte R, Heurich M, Valdes-Cañedo F, et al. Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation. *J Clin Invest*. 2010;120(10):3702-3712. doi:10.1172/JCI43343

9. Chauvet S, Roumenina LT, Bruneau S, et al. A Familial C3GN Secondary to Defective C3 Regulation by Complement Receptor 1 and Complement Factor H. *J Am Soc Nephrol*. 2015;27(6):1665. doi:10.1681/ASN.2015040348

10. Servais A, Noël LH, Roumenina LT, et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. *Kidney Int*. 2012;82(4):454-464. doi:10.1038/KI.2012.63

11. Iatropoulos P, Noris M, Mele C, et al. Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome. *Mol Immunol*. 2016;71:131-142. doi:10.1016/J.MOLIMM.2016.01.010

12. Bu F, Borsa NG, Jones MB, et al. High-throughput genetic testing for thrombotic microangiopathies and C3 glomerulopathies. *Journal of the American Society of Nephrology*. 2016;27(4):1245-1253. doi:10.1681/ASN.2015040385/-/DCSUPPLEMENTAL

13. Levine AP, Chan MMY, Sadeghi-Alavijeh O, et al. Large-Scale Whole-Genome Sequencing Reveals the Genetic Architecture of Primary Membranoproliferative GN and C3 Glomerulopathy. *J Am Soc Nephrol*. 2020;31(2):365-373. doi:10.1681/ASN.2019040433

14. Afolabi H, Zhang BM, O'Shaughnessy M, Chertow GM, Lafayette R, Charu V. The Association of Class I and II Human Leukocyte Antigen Serotypes With End-Stage Kidney Disease Due to Membranoproliferative Glomerulonephritis and Dense Deposit Disease. *Am J Kidney Dis*. 2024;83(1):79-89. doi:10.1053/J.AJKD.2023.06.005

15. Iatropoulos P, Daina E, Curreri M, et al. Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN. *J Am Soc Nephrol*. 2018;29(1):283-294. doi:10.1681/ASN.2017030258

16. Chiara Marinozzi M, Roumenina LT, Chauvet S, et al. Anti-Factor B and Anti-C3b Autoantibodies in C3 Glomerulopathy and Ig-Associated Membranoproliferative GN. *J Am Soc Nephrol*. 2017;28(5):1603-1613. doi:10.1681/ASN.2016030343

17. Caravaca-Fontán F, Díaz-Encarnación MM, Lucientes L, et al. Mycophenolate Mofetil in C3 Glomerulopathy and Pathogenic Drivers of the Disease. *Clin J Am Soc Nephrol*. 2020;15(9):1287-1298. doi:10.2215/CJN.15241219

18. Bomback AS, Santoriello D, Avasare RS, et al. C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy. *Kidney Int*. 2018;93(4):977-985. doi:10.1016/J.KINT.2017.10.022

19. Wong EKS, Marchbank KJ, Lomax-Browne H, et al. C3 Glomerulopathy and Related Disorders in Children: Etiology-Phenotype Correlation and Outcomes. *Clin J Am Soc Nephrol*. 2021;16(11):1639-1651. doi:10.2215/CJN.00320121

20. Lomax-Browne HJ, Medjeral-Thomas NR, Barbour SJ, et al. Association of Histologic Parameters with Outcome in C3 Glomerulopathy and Idiopathic Immunoglobulin-Associated Membranoproliferative Glomerulonephritis. *Clinical Journal of the American Society of Nephrology*. 2022;17(7):994-1007. doi:10.2215/CJN.16801221/-/DCSUPPLEMENTAL

21. Caravaca-Fontán F, Trujillo H, Alonso M, et al. Validation of a Histologic Scoring Index for C3 Glomerulopathy. *Am J Kidney Dis*. 2021;77(5):684-695.e1. doi:10.1053/J.AJKD.2020.11.011

22. Kirpalani A, Jawa N, Smoyer WE, et al. Long-Term Outcomes of C3 Glomerulopathy and Immune-Complex Membranoproliferative Glomerulonephritis in Children. *Kidney Int Rep*. 2020;5(12):2313-2324. doi:10.1016/J.EKIR.2020.09.019

23. Nakagawa N, Mizuno M, Kato S, et al. Demographic, clinical characteristics and treatment outcomes of immune-complex membranoproliferative glomerulonephritis and C3 glomerulonephritis in Japan: A retrospective analysis of data from the Japan Renal Biopsy Registry. *PLoS One*. 2021;16(9). doi:10.1371/JOURNAL.PONE.0257397

24. Ravindran A, Fervenza FC, Smith RJH, De Vriese AS, Sethi S. C3 Glomerulopathy: Ten Years' Experience at Mayo Clinic. *Mayo Clin Proc*. 2018;93(8):991-1008. doi:10.1016/J.MAYOCP.2018.05.019

25. Chauvet S, Hauer JJ, Petitprez F, et al. Results from a nationwide retrospective cohort measure the impact of C3 and soluble C5b-9 levels on kidney outcomes in C3 glomerulopathy. *Kidney Int*. 2022;102(4):904-916. doi:10.1016/J.KINT.2022.05.027

26. Caravaca-Fontán F, Díaz-Encarnación M, Cabello V, et al. Longitudinal change in proteinuria and kidney outcomes in C3 glomerulopathy. *Nephrol Dial Transplant*. 2022;37(7):1270-1280. doi:10.1093/NDT/GFAB075

27. Caravaca-Fontán F, Toledo-Rojas R, Huerta A, et al. Comparative Analysis of Proteinuria and Longitudinal Outcomes in Immune Complex Membranoproliferative Glomerulonephritis and C3 Glomerulopathy. *Kidney Int Rep*. 2025;0(0). doi:10.1016/j.ekir.2025.01.024

28. Stevens LA, Greene T, Levey AS. Surrogate end points for clinical trials of kidney disease progression. *Clin J Am Soc Nephrol*. 2006;1(4):874-884. doi:10.2215/CJN.00600206

29. Levey AS, Gansevoort RT, Coresh J, et al. Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency. *Am J Kidney Dis*. 2020;75(1):84-104. doi:10.1053/J.AJKD.2019.06.009

30. Nester C, Decker DA, Meier M, et al. Developing Therapies for C3 Glomerulopathy: Report of the Kidney Health Initiative C3 Glomerulopathy Trial Endpoints Work Group. *Clin J Am Soc Nephrol*. 2024;19(9):1201-1208. doi:10.2215/CJN.0000000000000505

31. Grams ME, Sang Y, Ballew SH, et al. Evaluating Glomerular Filtration Rate Slope as a Surrogate End Point for ESKD in Clinical Trials: An Individual Participant Meta-Analysis of Observational Data. *J Am Soc Nephrol*. 2019;30(9):1746-1755. doi:10.1681/ASN.2019010008

32. Inker LA, Heerspink HJL, Tighiouart H, et al. GFR slope as a surrogate end point for kidney disease progression in clinical trials: A meta-analysis of treatment effects of randomized controlled trials. *Journal of the American Society of Nephrology*. 2019;30(9):1735-1745. doi:10.1681/ASN.2019010007/-/DCSUPPLEMENTAL

33. Inker LA, Collier W, Greene T, et al. A meta-analysis of GFR slope as a surrogate endpoint for kidney failure. *Nat Med*. 2023;29(7):1867-1876. doi:10.1038/S41591-023-02418-0

34. Heerspink HJL, Greene T, Tighiouart H, et al. Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. *Lancet Diabetes Endocrinol*. 2019;7(2):128-139. doi:10.1016/S2213-8587(18)30314-0

35. Thompson A, Carroll K, Inker LA, et al. Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy. *Clin J Am Soc Nephrol*. 2019;14(3):469-481. doi:10.2215/CJN.08600718

36. Inker LA, Mondal H, Greene T, et al. Early Change in Urine Protein as a Surrogate End Point in Studies of IgA Nephropathy: An Individual-Patient Meta-analysis. *Am J Kidney Dis*. 2016;68(3):392-401. doi:10.1053/J.AJKD.2016.02.042

37. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. *Stat Med*. 1989;8(4):431-440. doi:10.1002/SIM.4780080407

38. Inker LA, Heerspink HJL, Tighiouart H, et al. Association of Treatment Effects on Early Change in Urine Protein and Treatment Effects on GFR Slope in IgA Nephropathy: An Individual Participant Meta-analysis. *Am J Kidney Dis*. 2021;78(3):340-349.e1. doi:10.1053/J.AJKD.2021.03.007

39. Wong K, Pitcher D, Braddon F, et al. Description and Cross-Sectional Analyses of 25,880 Adults and Children in the UK National Registry of Rare Kidney Diseases Cohort. *Kidney Int Rep*. 2024;9(7):2067-2083. doi:10.1016/J.EKIR.2024.04.062

40. Salvadori M, Rosso G. Reclassification of membranoproliferative glomerulonephritis: Identification of a new GN: C3GN. *World J Nephrol*. 2016;5(4):308. doi:10.5527/WJN.V5.I4.308

41. Levine AP, Chan MMY, Sadeghi-Alavijeh O, et al. Large-Scale Whole-Genome Sequencing Reveals the Genetic Architecture of Primary Membranoproliferative GN and C3 Glomerulopathy. *J Am Soc Nephrol*. 2020;31(2):365-373. doi:10.1681/ASN.2019040433

42. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. *Ann Intern Med*. 2009;150(9):604-612. doi:10.7326/0003-4819-150-9-200905050-00006

43. Schwartz GJ, Muñoz A, Schneider MF, et al. New equations to estimate GFR in children with CKD. *J Am Soc Nephrol*. 2009;20(3):629-637. doi:10.1681/ASN.2008030287

44. Levin A, Agarwal R, Herrington WG, et al. International consensus definitions of clinical trial outcomes for kidney failure: 2020. *Kidney Int*. 2020;98(4):849-859. doi:10.1016/J.KINT.2020.07.013

45. Wong K, Pitcher D, Braddon F, et al. Effects of rare kidney diseases on kidney failure: a longitudinal analysis of the UK National Registry of Rare Kidney Diseases (RaDaR) cohort. *The Lancet*. 2024;403(10433):1279-1289. doi:10.1016/S0140-6736(23)02843-X

46. Annual Activity Report - ODT Clinical - NHS Blood and Transplant. Accessed March 13, 2025. https://www.odt.nhs.uk/statistics-and-reports/annual-activity-report/

47. Organ specific reports - ODT Clinical - NHS Blood and Transplant. Accessed March 13, 2025. https://www.odt.nhs.uk/statistics-and-reports/organ-specific-reports/

48. 26th Annual Report - data to 31/12/2022 | UK Kidney Association. Accessed March 13, 2025. https://www.ukkidney.org/audit-research/annual-report/26th-annual-report-data-31122022

49. Khandelwal P, Bhardwaj S, Singh G, Sinha A, Hari P, Bagga A. Therapy and outcomes of C3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis. *Pediatr Nephrol*. 2021;36(3):591-600. doi:10.1007/S00467-020-04736-8

Figure Legends

Figure 1: Study flow diagram and inclusion/exclusion criteria

Figure 2: Kaplan-Meier of time to kidney failure by disease subgroup (Panel A). Adjusted eGFR slope over full duration of follow-up truncated at 5 years by disease subgroup* (Panel B)

Figure 3: Forest plots of UPCR and eGFR changes within 2 years of diagnosis and hazard ratio of kidney failure for C3GN and IC-MPGN

Figure 4: Kaplan-Meier of time to kidney failure according to UPCR category at diagnosis (Panel a) and 12 months (Panel b), for C3G and IC-MPGN

Table 1: Baseline demographics and outcomes

	C3 Glomerulopathy				IC-MPGN	
	C3GN		DDD			
	N = 138	(%)[a]	N = 65	(%) [a]	N = 168	(%) [a]
Age at diagnosis (years)	N = 138		N = 65		N = 168	
Median (IQR)	24 (14 - 46)		14 (10 - 34)		25 (10 – 54)	
Pediatric (<18 years)	50	(36)	41	(63)	73	(43)
Sex	N = 138		N = 65		N = 168	
Female	54	(39)	31	(48)	81	(48)
Ethnicity	N = 126		N = 58		N = 157	
White	113	(90)	47	(81)	139	(89)
Median follow up duration	N = 138		N = 65		N = 168	
Median (IQR), years	10.6 (9.4– 11.2)		10.6 (8.9 – 18.0)		12.0 (7.5 – 15.6)	
Serum albumin at diagnosis	N = 60		N = 38		N = 92	
Mean (SD), g/l	32 (10)		29 (8)		28 (8)	
Complement C3 levels at diagnosis	N = 48		N = 27		N = 45	
Median (IQR), g/l	0.41 (0.20 – 1.01)		0.36 (0.12 - 0.73)		0.64 (0.17 - 0.94)	
Complement C4 levels at diagnosis	N = 48		N = 26		N = 44	
Median (IQR), g/l	0.25 (0.16 - 0.33)		0.22 (0.15 - 0.31)		0.14 (0.09 - 0.25)	
Kidney failure event	N = 138		N = 65		N = 168	
Yes	57	(41)	29	(45)	62	(37)
Immunosuppression within 1 year of diagnosis	N = 110		N = 53		N = 129	
Yes	42	(38)	22	(42)	63	(49)
RAS inhibitor within 1 year of diagnosis	N = 110		N = 53		N = 129	
Yes	44	(40)	23	(43)	54	(42)
eGFR/Proteinuria analysis population						
	C3G (C3GN/DDD)				IC-MPGN	
	N = 44			(%)	N = 47	(%)
UPCR (Median IQR, mg/mmol)						
Diagnosis	532 (301 - 915)				581 (310 - 847)	
6-month	148 (81 - 312)				130 (44 - 295)	
12-month	117 (55 - 321)				102 (25 – 360)	
eGFR at diagnosis						
Median (IQR), ml/min per 1.73 m^2	70 (40 - 94)				73 (41 - 114)	

[a]Percentages are proportions of those with data available. C3GN-C3 Glomerulonephritis, DDD- Dense Deposit Disease, IC-MPGN- Immune-Complex Membranoproliferative Glomerulonephritis, IQR- interquartile range, eGFR – estimated glomerular filtration rate, UPCR- urine protein creatinine ratio, RAS- renal angiotensin system.

Table 2: Univariable and multivariable cox model of time to kidney failure according to baseline characteristics for C3G and IC-MPGN

	Univariable Analysis		Multivariable Analysis		Univariable Analysis		Multivariable Analysis	
	Hazard Ratio (95% Confidence Interval)	*P* value	Hazard Ratio (95% Confidence Interval)	*P* value	Hazard Ratio (95% Confidence Interval)	*P* value	Hazard Ratio (95% Confidence Interval)	*P* value
	C3G				IC-MPGN			
Age at diagnosis, per 10 years	1.25 (1.12, 1.38)	**<0.0001**	1.10 (0.98, 1.24)	0.1001	1.22 (1.1, 1.35)	0.0002	1.15 (1.02, 1.30)	0.0239
Female	0.55 (0.35, 0.86)	0.0087	0.54 (0.34, 0.85)	0.0084	0.67 (0.4, 1.11)	0.1185	0.56 (0.33, 0.96)	0.0358
CKD stage at diagnosis								
1&2	Ref		ref		Ref			
3	2.42 (1.19, 4.93)	0.0151	1.67 (0.79-3.55)	0.1810	2.67 (1.22, 5.8)	0.0141	1.69 (0.75, 3.82)	0.2066
4	16.02 (7.85, 32.68)	**<0.0001**	12.63 (5.82, 27.41)	**<0.0001**	6.79 (2.69, 17.11)	**<0.0001**	3.56 (1.26, 10.01)	0.0163
Albumin								
<30 g/l	Ref				Ref			
≥30 g/l	0.71 (0.35, 1.43)	0.3370			0.93 (0.44, 1.97)	0.8541		
Complement C3 g/l	1.01 (0.99, 1.02)	0.3476			0.96 (0.75, 1.22)	0.7129		
Complement C4 g/l	1.03 (0.99, 1.08)	0.1669			0.87 (0.48, 1.58)	0.6380		
UPCR at diagnosis								
>300 mg/mmol	Ref				Ref			
100-300 mg/mmol	0.45 (0.19, 1.06)	0.0678			0.51 (0.18-1.48)	0.2154		
<100 mg/mmol	0.36 (0.13, 1.00)	0.0495			0.33 (0.04, 2.42)	0.2746		
UPCR at 12 months								
>300 mg/mmol	Ref				Ref			
100-300 mg/mmol	0.69 (0.29, 1.68)	0.4168	0.85 (0.34, 2.12)	0.7220	0.47 (0.15, 1.44)	0.1837	0.34 (0.11, 1.06)	0.0623
<100 mg/mmol	0.18 (0.06, 0.49)	**0.0010**	0.21 (0.073, 0.596)	0.0035	NE	-	NE	-
Immunosuppression in year 1	1.23 (0.64, 2.35)	0.5292			0.66 (0.29. 1.48)	0.3120		

*Patients were censored at death. C3 Glomerulopathy – C3 Glomerulonephritis and Dense Deposit Disease, IC-MPGN- Immune-complex MPGN, CKD- chronic kidney disease, UPCR- urine protein creatinine ratio, eGFR- estimated glomerular filtration rate NE- No events

Table 3. UPCR thresholds and changes in UPCR in the 1st 12 months following diagnosis and risk of kidney failure for C3G and IC-MPGN

UPCR thresholds at 12 months and Hazard Ratio (95% Confidence Interval) of Kidney Failure			50% decline in UPCR and Hazard Ratio (95% Confidence Interval) of Kidney Failure[a]				50mg/mmol decline in UPCR and Hazard Ratio (95% Confidence Interval) of Kidney Failure[a]			
C3 Glomerulopathy (C3 Glomerulonephritis and Dense Deposit Disease) N = 44										
UPCR Threshold[b]	**Adjusted HR[c]**	***P* value**	**Timepoint from**	**Timepoint to**	**Adjusted HR[d]**	***P* value**	**Timepoint from**	**Timepoint to**	**Adjusted HR [d]**	***P* value**
<100 mg/mmol	0.18 (0.05, 0.65)	0.0086	**Diagnosis**	**6 months**	0.61 (0.35, 1.08)	0.0898	**Diagnosis**	**6 months**	0.87 (0.65, 1.18)	0.3767
<200 mg/mmol	0.13 (0.04, 0.43)	0.0009	**Diagnosis**	**1 year**	0.4 (0.23, 0.69)	0.0010	**Diagnosis**	**1 year**	0.62 (0.43, 0.91)	0.0136
<300 mg/mmol	0.26 (0.1, 0.67)	0.0054	**6 months**	**1 year**	0.33 (0.14, 0.76)	0.0097	**6 months**	**1 year**	0.71 (0.51, 1.00)	0.0435
Immune Complex MPGN N = 47										
<100 mg/mmol	NE	NE	**Diagnosis**	**6 months**	0.66 (0.42, 1.04)	0.0698	**Diagnosis**	**6 months**	0.72 (0.51, 1.01)	0.0597
<200 mg/mmol	0.03 (0.004, 0.25)	0.0011	**Diagnosis**	**1 year**	0.22 (0.1, 0.49)	0.0002	**Diagnosis**	**1 year**	0.52 (0.35, 0.79)	0.0018
<300 mg/mmol	0.04 (0.01, 0.24)	0.0004	**6 months**	**1 year**	0.12 (0.03, 0.58)	0.0079	**6 months**	**1 year**	0.062 (0.008, 0.50)	0.009
Combined cohort (C3 Glomerulopathy and Immune Complex MPGN) N = 91										
<100 mg/mmol	0.10 (0.03, 0.30)	<0.0001	**Diagnosis**	**6 months**	0.62 (0.44, 0.86)	0.0048	**Diagnosis**	**6 months**	0.79 (0.65, 0.96)	0.0183
<200 mg/mmol	0.13 (0.06, 0.31)	<0.0001	**Diagnosis**	**1 year**	0.40 (0.28, 0.56)	<0.0001	**Diagnosis**	**1 year**	0.63 (0.50, 0.78)	<0.0001
<300 mg/mmol	0.15 (0.07, 0.34)	<0.0001	**6 months**	**1 year**	0.26 (0.13, 0.50)	<0.0001	**6 months**	**1 year**	0.63 (0.48, 0.82)	0.0007

[a]Analyses exclude those with UPCR <50mg/mmol at diagnosis [b] Comparison of patients who do and do not reach each threshold [c] Adjusted for age, sex and eGFR [d]Adjusted for eGFR, age, sex and baseline UPCR. NE= Not Estimable

Figure 1: Study flow diagram and inclusion/exclusion criteria



Figure 2. Kaplan-Meier of time to kidney failure by disease subgroup (Panel A). Adjusted eGFR slope over full duration of follow-up truncated at 5 years by disease subgroup* (Panel B)



*Adjusted for baseline eGFR, sex and age

Figure 3: Forest plots of UPCR and eGFR changes within 2 years of diagnosis and hazard ratio of kidney failure for C3GN and IC-MPGN



*Adjusted for age, sex and eGFR at diagnosis

Figure 4: Kaplan-Meier of time to kidney failure according to UPCR category at diagnosis (Panel a) and 12 months (Panel b), for C3G and IC-MPGN



National Registry of Rare Kidney Diseases (RaDaR) Consortium

Sharirose Abat,[1] Shazia Adalat,[2] Joy Agbonmwandolor,[3] Zubaidah Ahmad,[4] Abdulfattah Alejmi,[5] Rashid Almasarwah,[6] Nicholas Annear,[1] Ellie Asgari,[4] Amanda Ayers,[7] Jyoti Baharani,[8] Gowrie Balasubramaniam,[9] Felix Jo-Bamba Kpodo,[10] Tarun Bansal,[11] Alison Barratt,[12] Jonathan Barratt[79], Megan Bates,[13] Natalie Bayne,[14] Janet Bendle,[15] Sarah Benyon,[16] Carsten Bergmann,[17,18] Sunil Bhandari,[19] Coralie Bingham,[20] Preetham Boddana,[21] Sally Bond,[22] Fiona Braddon,[23] Kate Bramham,[23] Angela Branson,[15] Stephen Brearey,[24] Vicky Brocklebank,[25] Sharanjit Budwal,[26] Conor Byrne,[27] Hugh Cairns,[28] Brian Camilleri[29], Gary Campbell[30], Alys Capell[31], Margaret Carmody,[8] Marion Carson[32], Tracy Cathcart,[19] Christine Catley,[9] Karine Cesar[33], Melanie Chan,[6] Houda Chea,[15] James Chess[34], Chee Kay Cheung,[26] Katy-Jane Chick[35], Nihil Chitalia[36], Martin Christian[37], Tina Chrysochou[38,39], Katherine Clark[40], Christopher Clayton[41], Rhian Clissold,[20] Helen Cockerill[33], Joshua Coelho[42], Elizabeth Colby[43], Viv Colclough[44], Eileen Conway[45], H. Terence Cook[46], Wendy Cook[47], Theresa Cooper[48], Richard J Coward[43], Sarah Crosbie,[22] Gabor Cserep[49], Anjali Date[50], Katherine Davidson[48], Amanda Davies[51], Neeraj Dhaun[52], Ajay Dhaygude[53], Lynn Diskin,[12] Abhijit Dixit[41,54], Eunice Ann Doctolero[35], Suzannah Dorey[55], Lewis Downard,[23] Mark Drayson[56], Gavin Dreyer,[27] Tina Dutt[57], Kufreabasi Etuk,[28] Dawn Evans[58], Jenny Finch[29], Frances Flinter[59], James Fotheringham[60], Lucy Francis[82], Daniel P. Gale[61], Hugh Gallagher[62], David Game,[4] Eva Lozano Garcia[42], Madita Gavrila,[22] Susie Gear[63], Colin Geddes[64], Mark Gilchrist[65], Matt Gittus[66], Paraskevi Goggolidou[67], Christopher Goldsmith[57], Patricia Gooden[68], Andrea Goodlife,[26] Priyanka Goodwin[53], Tassos Grammatikopoulos,[28,69] Barry Gray[70], Megan Griffith[46], Steph Gumus,[9] Sanjana Gupta[71], Patrick Hamilton[72], Lorraine Harper[56], Tess Harris[73], Louise Haskell[74], Samantha Hayward[43], Shivaram Hegde[75], Bruce Hendry[76], Sue Hewins[77], Nicola Hewitson[78], Kate Hillman,[15] Mrityunjay Hiremath[57], Alexandra Howson[79], Zay Htet,[28] Sharon Huish,[16] Richard Hull,[1] Alister Humphries[68], David P. J. Hunt[119], Karl Hunter[80], Samantha Hunter,[19] Marilyn Ijeomah-Orji,[6] Nick Inston[81], David Jayne[82], Gbemisola Jenfa[31], Alison Jenkins[83], Sally Johnson[118], Caroline A Jones[84], Colin Jones[85], Amanda Jones,[5] Rachel Jones[82], Lavanya Kamesh[81], Durga Kanigicherla[39], Fiona Karet Frankl[82], Mahzuz Karim[86], Amrit Kaur[87], David Kavanagh,[25] Kelly Kearley[88], Larissa Kerecuk,[14] Arif Khwaja[70], Garry King,[23] Grant King[89], Ewa Kislowska,[4] Edyta Klata[29], Maria Kokocinska,[14] Ania Koziell[2] Mark Lambie[90], Laura Lawless[41], Thomas Ledson[80], Rachel Lennon[91], Adam P Levine[92], Ling Wai Maggie Lai,[16] Graham Lipkin[81], Graham Lovitt[93], Paul Lyons[94], Holly Mabillard[95], Katherine Mackintosh,[7] Khalid Mahdi[96], Eamonn Maher[97], Kevin J. Marchbank,[25] Patrick B Mark[64], Sherry Masoud,[23] Bridgett Masunda,[9] Zainab Mavani[31], Jake Mayfair,[4] Stephen McAdoo,[6] Joanna Mckinnell[98], Nabil Melhem,[2] Simon Meyrick[51], Shabbir Moochhala[61], Putnam Morgan[99], Ann Morgan[100,101], Fawad Muhammad,[5] Shona Murray[30], Kristina Novobritskaya,[22] Albert CM Ong[66,70], Louise Oni[102], Kate Osmaston,[23] Neal Padmanabhan[64], Sharon Parkes,[14] Jean Patrick,[7] James Pattison,[4] Riny Paul,[1] Rachel Percival[103], Stephen J. Perkins[104], Alexandre Persu[105,106], William G Petchey[107], Matthew C. Pickering[46], Jennifer Pinney[81], David Pitcher,[23] Lucy Plumb[43], Zoe Plummer,[23] Joyce Popoola,[1] Frank Post,[28] Albert Power[83], Guy Pratt[56], Charles Pusey[46], Susan Pywell[23], Ria Rabara,[22] May Rabuya,[4]Tina Raju[42], Chadd Javier[108], Ian SD Roberts,[22] Candice Roufosse[109], Adam Rumjon,[28] Alan Salama[61], Moin Saleem[43], RN Sandford[97], Kanwaljit S. Sandu[110], Nadia Sarween[81], John A. Sayer[95], Neil Sebire[111,112], Haresh Selvaskandan,[26] Sapna Shah,[28] Asheesh Sharma[57], Edward J Sharples,[22] Neil Sheerin,[25] Harish Shetty[53], Rukshana Shroff[112], Roslyn Simms[70], Manish Sinha,[2] Smeeta Sinha[113], Kerry Smith[29], Lara Smith,[15] Shalabh Srivastava[114], Retha Steenkamp,[23] Ian Stott[115], Katerina Stroud[97], Pauline Swift[42], Justyna Szklarzewicz,[26] Fred Tam[46], Kay Tan[116], Robert Taylor[117], Marc Tischkowitz[97], Kay Thomas,[4] Yincent Tse[118], Alison Turnbull[85], A. Neil Turner[119], Kay Tyerman[55], Miranda Usher[120], Gopalakrishnan Venkat-Raman[121], Alycon Walker[122], Stephen B. Walsh[61], Aoife Waters[123], Angela Watt[68], Phil Webster,[6] Ashutosh Wechalekar[124], Gavin Iain Welsh[43], Nicol West[125], David Wheeler[61], Kate Wiles,[27] Lisa Willcocks[107], Angharad Williams[33], Emma Williams[29], Karen Williams,[4] Deborah H Wilson[126], Patricia D. Wilson[127], Paul Winyard,[9] Edwin Wong,[25] Katie Wong,[23] Grahame Wood[58], Emma Woodward,[15] Len Woodward[128], Adrian Woolf[129], and David Wright[71]

1 St George's University Hospitals NHS Foundation Trust, UK

2 Evelina London Children's Hospital, UK

3 David Evans Medical Research Centre, Nottingham University Hospital NHS Trust, UK

4 Guy's and St Thomas NHS Foundation Trust, UK

5 Ysbyty Gwynedd, Betsi Cadwaladr University Health Board, UK

6 Imperial College Healthcare NHS Trust, UK

7 James Paget University Hospital NHS Foundation Trust, UK

8 Heart of England NHS Foundation Trust, Birmingham, UK

9 Mid and South Essex NHS Foundation Trust, UK

10 Royal Berkshire NHS Foundation Trust, UK

11 Bradford Teaching Hospitals NHS Foundation Trust, UK

12 Royal United Hospital Bath NHS Trust, UK

13 Freeman Hospital, Newcastle Upon Tyne, UK

14 Birmingham Women's and Children's NHS Foundation Trust, UK

15 Manchester University NHS Foundation Trust, UK

16 Royal Devon University Healthcare NHS Foundation Trust, UK

17 Medizinische Genetik Mainz, Mainz, Germany

18 Department of Medicine, Faculty of Medicine, Medical Center-University of Freiburg, Freiburg, Germany

19 Hull University Teaching Hospitals NHS Trust, UK

20 Exeter Kidney Unit, Royal Devon University Healthcare NHS Foundation Trust, UK

21 Gloucestershire Hospitals NHS Foundation Trust, UK

22 Oxford University Hospitals NHS Foundation Trust, UK

23 UK Kidney Association, UK

24 Countess of Chester NHS Foundation Trust, UK

25 National Renal Complement Therapeutics Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK

26 University Hospitals of Leicester NHS Trust, UK

27 Barts Health NHS Trust, London, UK

28 King's College Hospital NHS Foundation Trust, UK

29 East Suffolk and North Essex NHS Foundation Trust, UK

30 Ninewells Hospital and Medical School, Dundee, UK

31 North West Anglia NHS Foundation Trust, UK

32 Northern Health and Social Care Trust and Northern Ireland Clinical Research Network

33 West Suffolk NHS Foundation Trust, UK

34 Morriston Hospital, Swansea Bay Health Board, UK

35 Lister Hospital, East and North Hertfordshire NHS Trust, UK

36 Dartford and Gravesham NHS Trust, UK

37 Nottingham Children's Hospital, UK

38 Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Salford, UK

39 University of Manchester, UK

40 King's College London, UK

41 Nottingham University Hospitals NHS Trust, UK

42 Epsom and St Helier University Hospitals NHS Trust, UK

43 University of Bristol Medical School, Bristol, UK

44 Royal Stoke University Hospital, UK

45 Manchester Royal Infirmary, UK

46 Centre for Inflammatory Disease, Imperial College London, UK

47 Nephrotic Syndrome Trust (NeST), UK

48 North Cumbria Integrated Care NHS Foundation Trust, UK

49 Colchester General Hospital, UK

50 Tameside and Glossop Integrated Care NHS Foundation Trust, UK

51 Wye Valley NHS Trust, UK

52 BHF Centre for Cardiovascular Science, The Queen's Medical Research Institute, University of Edinburgh, UK

53 Lancashire Teaching Hospital, UK

54 School of Medicine, University of Nottingham, UK

55 Leeds Teaching Hospitals NHS Trust, UK

56 University of Birmingham, UK

57 Liverpool University Hospitals Foundation NHS Trust, UK

58 Salford Royal NHS Foundation Trust, UK

59 Department of Clinical Genetics, Guy's and St Thomas' NHS Foundation Trust, UK

60 Centre for Health and Related Research, School of Population Health, University of Sheffield, UK

61 University College London Department of Renal Medicine, Royal Free Hospital, UK

62 SW Thames Renal Unit, Epsom and St Helier University Hospitals NHS Trust, UK

63 Alport UK, UK

64 Queen Elizabeth University Hospital, Glasgow, UK

65 College of Medicine and Health, University of Exeter, UK

66 Division of Population Health, University of Sheffield, UK

67 University of Wolverhampton, UK

68 Patient Representative, UK

69 Institute of Liver Studies, King's College London, UK

70 Sheffield Kidney Institute, Sheffield Teaching Hospitals NHS Foundation Trust, UK

71 Royal Free Hospital, UK

72 Manchester Institute of Nephrology and Transplantation, Manchester Royal Infirmary, UK

73 PKD Charity, UK

74 University Hospital Southampton NHS Foundation Trust, UK

75 Children's Kidney Centre, University Hospital of Wales, UK

76 Travere Therapeutics, UK

77 University Hospitals Coventry and Warwickshire NHS Trust, UK

78 County Durham & Darlington NHS Foundation Trust, UK

79 University of Leicester, UK

80 Wirral University Teaching Hospital NHS Foundation Trust, UK

81 University Hospitals Birmingham NHS Foundation Trust, UK

82 Department of Medicine, University of Cambridge, UK

83 North Bristol NHS Trust, UK

84 Alder Hey Children's NHS Foundation Trust, UK

85 York & Scarborough Teaching Hospitals NHS Foundation Trust, UK

86 Norfolk and Norwich University Hospitals NHS Trust, UK

87 Royal Manchester Children's Hospital, Manchester, UK

88 PTEN UK and Ireland Patient Group

89 HNF1B Support Group, UK

90 School of Medicine, Keele University, UK

91 Wellcome Centre for Cell-Matrix Research, University of Manchester, UK

92 Research Department of Pathology, University College London, UK

93 HLRCC Foundation, UK

94 Cambridge Institute of Therapeutic Immunology and Infectious Disease, Cambridge, UK

95 Newcastle University, UK

96 United Lincolnshire Hospitals NHS Trust, UK

97 Department of Medical Genetics, University of Cambridge, UK

98 University Hospitals of Derby and Burton NHS Foundation Trust, UK

99 Retroperitoneal Fibrosis (RF) Group, UK

100 National Institute of Health and Care Research Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, UK

101 School of Medicine, University of Leeds, UK

102 University of Liverpool, UK

103 Newcastle Upon Tyne Hospitals NHS Foundation Trust, UK

104 Research Department of Structural and Molecular Biology, University College London, UK

105 Division of Cardiology, Cliniques Universitaires Saint-Luc, Belgium

106 Pole of Cardiovascular Research, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium

107 Cambridge University Hospitals NHS Foundation Trust, UK

108 East and North Hertfordshire NHS Trust, UK

109 Department of Immunology and Inflammation, Faculty of Medicine, Imperial College London, UK

110 Shrewsbury and Telford Hospital NHS Trust, UK

111 National Institute of Health and Care Research Great Ormond Street Hospital Biomedical Research Centre, UK

112 UCL Great Ormond Street Institute of Child Health, UK

113 Northern Care Alliance NHS Foundation Trust, UK

114 South Tyneside and Sunderland NHS Foundation Trust, UK

115 Doncaster and Bassetlaw Teaching Hospitals, UK

116 New Cross Hospital, Wolverhampton, UK

117 Wellcome Centre for Mitochondrial Research, Translational & Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, UK

118 Great North Children's Hospital, Newcastle Upon Tyne, UK

119 University of Edinburgh, UK

120 Calderdale & Huddersfield Foundation Trust, UK

121 Royal Surrey County Hospital, Guildford, UK

122 South Tees Hospitals NHS Foundation Trust, UK

123 University College Cork, Ireland

124 National Amyloidosis Centre, University College London, UK

125 Great Western Hospital, Swindon, UK

126 North Tees and Hartlepool NHS Foundation Trust, UK

127 University College London, UK

128 aHUS Alliance, UK

129 School of Biological Sciences, University of Manchester, UK